Sangui Biotech International Inc represents a strong focus on innovation, commitment to excellence, and dedication to improving healthcare. The company's corporate philosophy centers around developing innovative medical technologies that address unmet medical needs. Sangui Biotech International Inc strives to create value for patients and shareholders alike through the development and commercialization of advanced therapeutic solutions. By leveraging their expertise in biotechnology, the company aims to contribute to the advancement of healthcare delivery and enhance patient outcomes. Sangui Biotech International Inc's commitment to research and development, combined with their patient-centric approach, positions them as a leader in the healthcare industry.

Sangui Biotech International Inc is primarily present in Germany, Switzerland, and the United States.

Sangui Biotech International Inc has achieved several significant milestones throughout its history. The company has successfully developed and patented its innovative Hemoglobin-based Oxygen Carrier (HBOC) technologies, which have shown promising results in the field of blood substitute development. Sangui Biotech has also received regulatory approvals for its products in various countries. Additionally, the company has entered into strategic collaborations with prominent healthcare organizations to further enhance the commercialization and distribution of its products. These milestones showcase Sangui Biotech International Inc's commitment to advancing healthcare technologies and expanding its global presence in the field of biotechnology.

Sangui Biotech International Inc is a globally recognized biotech company. Established in (insert year), it has a rich history of pioneering research and development in the field of (specify industry, e.g., biotechnology, pharmaceuticals). This innovative company aims to improve the quality of life for individuals through their cutting-edge products and solutions. Sangui Biotech International Inc has consistently demonstrated its commitment to scientific advancement, evidenced by its extensive portfolio of patents, partnerships, and successful clinical trials. With a global presence and a strong track record, Sangui Biotech International Inc represents a remarkable player in the (specify industry) sector, dedicated to revolutionizing healthcare practices worldwide.

The main competitors of Sangui Biotech International Inc in the market include companies like Johnson & Johnson, Pfizer Inc, Novartis AG, Roche Holding AG, and Abbott Laboratories.

Sangui Biotech International Inc is primarily active in the healthcare and biotechnology industries.

The business model of Sangui Biotech International Inc focuses on developing and commercializing pharmaceutical and medical-prophylactic products. With a strong emphasis on research and innovation, the company aims to address various medical conditions, primarily focusing on wound healing and cardiovascular diseases. Sangui Biotech International Inc utilizes its patented technology, involving the synthesis of oxygen and carbon dioxide transport molecules, to develop specific drug formulations for improved therapeutic outcomes. By leveraging its expertise in biomedical research and strategic partnerships, the company strives to provide advanced medical solutions to enhance patients' quality of life.

KGV untuk Sangui BioTech International saat ini tidak dapat dihitung.

KUV untuk Sangui BioTech International saat ini tidak dapat dihitung.

Skor Kualitas AlleAktien untuk Sangui BioTech International adalah 4/10.

Pendapatan untuk Sangui BioTech International saat ini tidak dapat dihitung.

Laba saat ini tidak bisa dihitung untuk Sangui BioTech International.

Sangui Biotech International Inc is a company specializing in the development and marketing of technologies and products in the field of medical care and healthcare. The company operates in various sectors and offers a wide range of products and technologies to meet the needs of different customers. The core business of Sangui Biotech is the development and marketing of biotechnological products and technologies. The company has filed a variety of patents to protect innovative technologies and bring them to market. The company works closely with other companies and institutions in the field of research and development to develop new technologies and products. One of the main sectors of Sangui Biotech is the marketing of products in the field of wound treatment. The company manufactures a wide range of products and technologies specifically designed for wound treatment. These products include various types of wound dressings that support the natural regeneration of skin tissue and enhance wound healing. The company also produces innovative wound dressings that are particularly used in infected wounds and surgery due to their antimicrobial properties and high absorbency. Another important sector of Sangui Biotech is the marketing of products in the field of blood tests. The company has developed a wide range of products and technologies that can be used for blood testing and analysis of blood samples. These products are of great benefit in medical diagnostics and drug research. The company is also involved in cancer diagnosis and specializes in the development of tests that can be used for early detection of cancer. The company manufactures various types of test kits that enable doctors and laboratory technicians to identify cancer cells in tissue and blood samples. Sangui Biotech collaborates with various institutions and companies to market its products and technologies worldwide. The company has expanded its presence in various countries and continuously works to expand its reach. The company also places a strong emphasis on collaboration with universities and research institutions to advance its research and development activities. Overall, Sangui Biotech is a company specializing in the development and marketing of products and technologies in the field of medical care. The company operates in various sectors and offers a wide range of products to meet the needs of different customers. The company is continuously striving to improve its products and services and expand its presence in the market.

Sangui BioTech International membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Sangui BioTech International saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Sangui BioTech International adalah US80105B1017.

WKN dari Sangui BioTech International adalah 906757.

Ticker dari Sangui BioTech International adalah SGBI.

Dalam 12 bulan terakhir, Sangui BioTech International membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Sangui BioTech International diperkirakan akan membayar dividen sebesar 0 USD.

Imbal hasil dividen dari Sangui BioTech International saat ini adalah .

Sangui BioTech International membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Sangui BioTech International membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

Sangui BioTech International dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Sangui BioTech International tanggal 4/11/2024 sejumlah 0 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 4/11/2024.

Pembayaran dividen terakhir dilakukan pada 4/11/2024.

Pada tahun 2023, Sangui BioTech International 0 USD telah dibayarkan sebagai dividen.

Dividen dari Sangui BioTech International dibayarkan dalam USD.